Why this matters
Modern stage II-III NSCLC increasingly sits at the intersection of surgery, systemic therapy, and radiotherapy.
Some patients begin treatment with curative-intent surgery planned, receive neoadjuvant systemic therapy, and are then found to be unresectable at multidisciplinary reassessment.
That creates a practical question: can these patients transition directly into a definitive chemoradiotherapy pathway without losing curative intent?
MDT-BRIDGE prospectively tested exactly that treatment pathway.
Patients initially treated with neoadjuvant durvalumab plus chemotherapy who became unresectable could switch to definitive CRT, followed by consolidation durvalumab.
The early results suggest that this multidisciplinary transition is feasible and can preserve a curative treatment strategy.
Study design
MDT-BRIDGE is a global, non-randomized phase II study in treatment-naive patients with EGFR and ALK wild-type stage IIB-IIIB NSCLC.
All patients underwent baseline multidisciplinary assessment of resectability.
Initial treatment consisted of:
- 2 cycles of neoadjuvant durvalumab plus chemotherapy every 3 weeks
Patients were then reassessed by the multidisciplinary team.
Those considered resectable continued neoadjuvant systemic therapy and proceeded toward surgery.
Patients considered unresectable transitioned to approximately 6 weeks of standard-of-care chemoradiotherapy.
After surgery or CRT, patients received durvalumab every 4 weeks for up to 1 year.
A total of 142 patients received neoadjuvant treatment.
At the first multidisciplinary reassessment, 21 patients were considered unresectable.
Ultimately, 25 patients received CRT:
- 21 with concurrent CRT
- 4 with sequential CRT
Mean radiation dose was 61.9 Gy, delivered in a median of 30 fractions.
Key results
Among the 25 patients treated with CRT, disease control after chemoradiotherapy was high.
Following CRT:
- 13 patients had an objective response
- 8 had stable disease
Overall, 84% had either objective response or stable disease.
Twenty-three of the 25 CRT-treated patients, or 92%, subsequently received consolidation durvalumab.
The reported 12-month progression-free survival rate was:
- 85.0%
- 95% CI 59.8-95.0
PFS was measured from the first durvalumab treatment dose.
Safety during chemoradiotherapy
During CRT:
- 28.0% experienced maximum grade 3-4 adverse events
- 4.0% discontinued treatment because of an adverse event
- 4.0% experienced an immune-mediated adverse event
- 8.0% developed grade 2 pneumonitis
The toxicity profile therefore appeared manageable within this small cohort.
Safety during consolidation durvalumab
During consolidation durvalumab:
- 17.4% experienced maximum grade 3-4 adverse events
- 13.0% discontinued because of adverse events
- 13.0% experienced immune-mediated adverse events
- 8.7% developed grade 2 pneumonitis
No unexpected safety signal was reported.
Interpretation
The most interesting aspect of MDT-BRIDGE is not the absolute PFS number.
It is the treatment pathway.
These patients entered the study as surgical candidates or borderline surgical candidates. After neoadjuvant durvalumab plus chemotherapy, some were reassessed as unresectable.
Rather than abandoning curative intent or improvising treatment outside a defined strategy, they transitioned to definitive CRT followed by consolidation durvalumab.
That is clinically relevant because modern multimodality NSCLC treatment is increasingly dynamic. Resectability is not always a fixed characteristic determined at diagnosis.
Tumor response, anatomy, nodal disease, technical operability, and multidisciplinary judgment can change during neoadjuvant treatment.
MDT-BRIDGE suggests that the PACIFIC-style pathway can function as a structured fallback when surgery is no longer appropriate.
The 12-month PFS rate of 85% is encouraging, but it should not dominate interpretation of the study.
Only 25 patients received CRT. The cohort was highly selected, and PFS was measured from the first durvalumab dose. These features make direct comparison with historical stage III datasets inappropriate.
The study therefore provides stronger evidence for feasibility of the treatment transition than for the magnitude of oncologic benefit.
Limitations
MDT-BRIDGE is non-randomized.
Only 25 patients received chemoradiotherapy.
The analysis therefore has limited statistical precision.
Patients entering the CRT cohort were selected through repeated multidisciplinary assessment rather than through random assignment.
The reported 12-month PFS estimate has a wide confidence interval.
PFS was measured from the first durvalumab dose, which complicates comparison with studies using different time origins.
Longer follow-up is required for mature progression-free survival and overall survival.
The study also does not establish whether the preceding neoadjuvant durvalumab plus chemotherapy improves outcomes compared with starting definitive CRT directly in patients ultimately found to be unresectable.